These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 33914703)

  • 1. PPARĪ³ agonists promote the resolution of myelofibrosis in preclinical models.
    Lambert J; Saliba J; Calderon C; Sii-Felice K; Salma M; Edmond V; Alvarez JC; Delord M; Marty C; Plo I; Kiladjian JJ; Soler E; Vainchenker W; Villeval JL; Rousselot P; Prost S
    J Clin Invest; 2021 Jun; 131(11):. PubMed ID: 33914703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remodeling the Bone Marrow Microenvironment - A Proposal for Targeting Pro-inflammatory Contributors in MPN.
    Jutzi JS; Mullally A
    Front Immunol; 2020; 11():2093. PubMed ID: 32983162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of mast cells and bone marrow reticulin fibrosis in patients with bcr-abl negative chronic myeloproliferative neoplasms.
    Keski H
    Blood Cells Mol Dis; 2020 May; 82():102420. PubMed ID: 32179412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Captopril mitigates splenomegaly and myelofibrosis in the Gata1
    Corey SJ; Jha J; McCart EA; Rittase WB; George J; Mattapallil JJ; Mehta H; Ognoon M; Bylicky MA; Summers TA; Day RM
    J Cell Mol Med; 2018 Sep; 22(9):4274-4282. PubMed ID: 29971909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
    Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
    PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice.
    Ozono Y; Shide K; Kameda T; Kamiunten A; Tahira Y; Sekine M; Akizuki K; Nakamura K; Iwakiri H; Sueta M; Hidaka T; Kubuki Y; Yamamoto S; Hasuike S; Sawaguchi A; Nagata K; Shimoda K
    Leukemia; 2021 Feb; 35(2):454-467. PubMed ID: 32472085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identity of Gli1
    Sena IFG; Prazeres PHDM; Santos GSP; Borges IT; Azevedo PO; Andreotti JP; Almeida VM; Paiva AE; Guerra DAP; Lousado L; Souto L; Mintz A; Birbrair A
    Exp Hematol; 2017 Oct; 54():12-16. PubMed ID: 28690072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond JAK-2: potential targets for myeloproliferative neoplasm therapy.
    Harrington PM; Harrison CN
    Expert Rev Hematol; 2018 Apr; 11(4):315-324. PubMed ID: 29516749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Still a burning question: the interplay between inflammation and fibrosis in myeloproliferative neoplasms.
    Gleitz HFE; Benabid A; Schneider RK
    Curr Opin Hematol; 2021 Sep; 28(5):364-371. PubMed ID: 34232140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model.
    Bianchi E; Rontauroli S; Tavernari L; Mirabile M; Pedrazzi F; Genovese E; Sartini S; Dall'Ora M; Grisendi G; Fabbiani L; Maccaferri M; Carretta C; Parenti S; Fantini S; Bartalucci N; Calabresi L; Balliu M; Guglielmelli P; Potenza L; Tagliafico E; Losi L; Dominici M; Luppi M; Vannucchi AM; Manfredini R
    Leukemia; 2023 May; 37(5):1068-1079. PubMed ID: 36928007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis.
    Rambaldi B; Diral E; Donsante S; Di Marzo N; Mottadelli F; Cardinale L; Dander E; Isimbaldi G; Pioltelli P; Biondi A; Riminucci M; D'Amico G; Elli EM; Pievani A; Serafini M
    Ann Hematol; 2021 Jan; 100(1):105-116. PubMed ID: 33089365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SOHO State of the Art Updates and Next Questions: Myelofibrosis.
    Pettit K; Verstovsek S; Talpaz M
    Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):191-199. PubMed ID: 30987952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional interdependence of hematopoietic stem cells and their niche in oncogene promotion of myeloproliferative neoplasms: the 159th biomedical version of "it takes two to tango".
    Zhan H; Kaushansky K
    Exp Hematol; 2019 Feb; 70():24-30. PubMed ID: 30593829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PPARĪ³ Modulation of Cytokine-Stimulated MUC16 (CA125) Expression in Breast and Ovarian Cancer-Derived Cells.
    Morgado M; Carson DD
    J Cell Biochem; 2017 Jan; 118(1):163-171. PubMed ID: 27292441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of pleckstrin-2 reverts lethality and vascular occlusions in JAK2V617F-positive myeloproliferative neoplasms.
    Zhao B; Mei Y; Cao L; Zhang J; Sumagin R; Yang J; Gao J; Schipma MJ; Wang Y; Thorsheim C; Zhao L; Stalker T; Stein B; Wen QJ; Crispino JD; Abrams CS; Ji P
    J Clin Invest; 2018 Jan; 128(1):125-140. PubMed ID: 29202466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneity in myeloproliferative neoplasms: Causes and consequences.
    O'Sullivan J; Mead AJ
    Adv Biol Regul; 2019 Jan; 71():55-68. PubMed ID: 30528537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesenchymal stem cells in myeloproliferative disorders - focus on primary myelofibrosis.
    Selicean SE; Tomuleasa C; Grewal R; Almeida-Porada G; Berindan-Neagoe I
    Leuk Lymphoma; 2019 Apr; 60(4):876-885. PubMed ID: 30277128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of ALK5 inhibition in myelofibrosis.
    Yue L; Bartenstein M; Zhao W; Ho WT; Han Y; Murdun C; Mailloux AW; Zhang L; Wang X; Budhathoki A; Pradhan K; Rapaport F; Wang H; Shao Z; Ren X; Steidl U; Levine RL; Zhao ZJ; Verma A; Epling-Burnette PK
    JCI Insight; 2017 Apr; 2(7):e90932. PubMed ID: 28405618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis.
    Yan D; Pomicter AD; Tantravahi S; Mason CC; Senina AV; Ahmann JM; Wang Q; Than H; Patel AB; Heaton WL; Eiring AM; Clair PM; Gantz KC; Redwine HM; Swierczek SI; Halverson BJ; Baloglu E; Shacham S; Khorashad JS; Kelley TW; Salama ME; Miles RR; Boucher KM; Prchal JT; O'Hare T; Deininger MW
    Clin Cancer Res; 2019 Apr; 25(7):2323-2335. PubMed ID: 30563936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of kinase inhibitors for hematologic malignancies: a systematic and critical review.
    Marchetti M
    Expert Rev Pharmacoecon Outcomes Res; 2017 Oct; 17(5):469-480. PubMed ID: 28796569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.